Sera Prognostics, Inc.

NasdaqGM SERA

Sera Prognostics, Inc. Price to Book Ratio (P/B) on January 14, 2025: 3.45

Sera Prognostics, Inc. Price to Book Ratio (P/B) is 3.45 on January 14, 2025, a 34.59% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Sera Prognostics, Inc. 52-week high Price to Book Ratio (P/B) is 5.08 on April 30, 2024, which is 47.11% above the current Price to Book Ratio (P/B).
Sera Prognostics, Inc. 52-week low Price to Book Ratio (P/B) is 2.32 on January 22, 2024, which is -32.76% below the current Price to Book Ratio (P/B).
Sera Prognostics, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 3.72.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqGM: SERA

Sera Prognostics, Inc.

CEO	Ms. Evguenia Lindgardt M.B.A.
IPO Date	July 15, 2021
Location	United States
Headquarters	2749 East Parleys Way
Employees	55
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals Research & Consulting

Description

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Key trends

Past 5 years